LXRX
Lexicon Pharmaceuticals, Inc.
$2.32
+0.00 (+0.00%)
At close · Jul 6
Market Cap
$1.03B
Shares
444,196,390
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.32
Open$2.30
Day$2.30–2.42
52W$0.84–2.68
Avg vol 30d3.5M
Short int25.4M · 5.7% float · 12.6d
Short vol65%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+46% above
+
Price vs 50-day avg
+14% above
◦
RSI (14)
58 · neutral
+
MACD trend
positive
◦
52-week position
80% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
+
Institutional flow
1 of 136 funds reported for Jun 30 · net +957 sh shares · +1 new
◦
Insider flow
No net insider activity over 90 days
+
Short interest
5.72% of float · ▼ -3.0% MoM · 12.6 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
136 holders — near 3-yr high, broad support
Fundamentals
Strong
+
Revenue growth
+60% Y/Y
+
EPS growth
+78% Y/Y
−
Free cash flow
$-67.9M
◦
Balance sheet
net debt $14.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+46% above
Bullish
Price vs 50-day avg
+14% above
Bullish
RSI (14)
58 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
80% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
1 of 136 funds reported for Jun 30 · net +957 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.72% of float · ▼ -3.0% MoM · 12.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
136 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 80%
52-wk high $3
vs 200-day avg +46%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LXRX
this stock
Lexicon Pharmaceuticals, Inc.
|
$1.03B | +101.7% | +60.2% | — | 5.7% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LXRX | -9.0% | +22.1% | +98.3% | -3.3% | +101.7% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -12.1% | +22.9% | +90.1% | -3.9% | +91.6% |